Video

Tarsus execs discuss origins, treating Demodex blepharitis

Author(s):

OT Staff Reports
Conferences|AAO

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

See more AAO coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
Related Content
(Image credit: AdobeStock/Anton Gvozdikov)
September 2nd 2025

When the world went virtual: How ophthalmology’s conferences stayed on track

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
September 2nd 2025

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
September 2nd 2025

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

Comparing micro-bypass implant + phaco vs phaco in POAG
September 2nd 2025

Comparing micro-bypass implant + phaco vs phaco in POAG

AAO 2024: 3D printed eyeglasses bring vision care to children in underserved, remote communities
September 2nd 2025

AAO 2024: 3D printed eyeglasses bring vision care to children in underserved, remote communities

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years
September 2nd 2025

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years

© 2025 MJH Life Sciences

All rights reserved.